Design And Development Of A Novel Formulation Of Pacritinib For Treatment Of Adults Intermediate And High Risk Myelofibrosis With Low Platelet Count. Journal of Pharmaceutical Negative Results, [S. l.], p. 649–652, 2023. DOI: 10.47750/pnr.2023.14.S01.84. Disponível em: https://www.pnrjournal.com/index.php/home/article/view/7066.. Acesso em: 3 jun. 2026.